CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo
- PMID: 16920943
- DOI: 10.4049/jimmunol.177.5.3063
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo
Abstract
The CD22 extracellular domain regulates B lymphocyte function by interacting with alpha2,6-linked sialic acid-bearing ligands. To understand how CD22 ligand interactions affect B cell function in vivo, mouse anti-mouse CD22 mAbs were generated that inhibit CD22 ligand binding to varying degrees. Remarkably, mAbs which blocked CD22 ligand binding accelerated mature B cell turnover by 2- to 4-fold in blood, spleen, and lymph nodes. CD22 ligand-blocking mAbs also inhibited the survival of adoptively transferred normal (73-88%) and malignant (90%) B cells in vivo. Moreover, mAbs that bound CD22 ligand binding domains induced significant CD22 internalization, depleted marginal zone B cells (82-99%), and reduced mature recirculating B cell numbers by 75-85%. The CD22 mAb effects were independent of complement and FcRs, and the CD22 mAbs had minimal effects in CD22AA mice that express mutated CD22 that is not capable of ligand binding. These data demonstrate that inhibition of CD22 ligand binding can disrupt normal and malignant B cell survival in vivo and suggest a novel mechanism of action for therapeutics targeting CD22 ligand binding domains.
Similar articles
-
CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.Front Immunol. 2018 Apr 19;9:820. doi: 10.3389/fimmu.2018.00820. eCollection 2018. Front Immunol. 2018. PMID: 29725338 Free PMC article.
-
CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12402-7. doi: 10.1073/pnas.1304888110. Epub 2013 Jul 8. Proc Natl Acad Sci U S A. 2013. PMID: 23836650 Free PMC article.
-
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.J Immunol. 2006 Sep 1;177(5):2994-3003. doi: 10.4049/jimmunol.177.5.2994. J Immunol. 2006. PMID: 16920935
-
Targeting CD22 in B-cell malignancies: current status and clinical outlook.BioDrugs. 2013 Aug;27(4):293-304. doi: 10.1007/s40259-013-0016-7. BioDrugs. 2013. PMID: 23696252 Review.
-
B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.Front Immunol. 2018 Dec 3;9:2820. doi: 10.3389/fimmu.2018.02820. eCollection 2018. Front Immunol. 2018. PMID: 30559744 Free PMC article. Review.
Cited by
-
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.Leukemia. 2013 Jan;27(1):170-82. doi: 10.1038/leu.2012.165. Epub 2012 Jul 13. Leukemia. 2013. PMID: 22713648 Free PMC article.
-
Role of IL-10-producing regulatory B cells in modulating T-helper cell immune responses during silica-induced lung inflammation and fibrosis.Sci Rep. 2016 Jun 29;6:28911. doi: 10.1038/srep28911. Sci Rep. 2016. PMID: 27354007 Free PMC article.
-
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.Cancer Immunol Immunother. 2009 Dec;58(12):2051-8. doi: 10.1007/s00262-009-0713-8. Epub 2009 May 13. Cancer Immunol Immunother. 2009. PMID: 19437017 Free PMC article.
-
Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo.J Exp Med. 2010 Jan 18;207(1):173-87. doi: 10.1084/jem.20091873. Epub 2009 Dec 28. J Exp Med. 2010. PMID: 20038598 Free PMC article.
-
IL-10-Producing B Cells Regulate T Helper Cell Immune Responses during 1,3-β-Glucan-Induced Lung Inflammation.Front Immunol. 2017 Apr 6;8:414. doi: 10.3389/fimmu.2017.00414. eCollection 2017. Front Immunol. 2017. PMID: 28428789 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources